Matthew Oberley: Our Latest Liquid Biopsy Study
Matthew Oberley, Chief Clinical Officer at Caris Life Sciences, shared on LinkedIn about a recent paper shared by J. Abraham et al. published in Nature:
“Just out – publication of our latest liquid biopsy study in Scientific Reports. I’m very excited about this work, which validates Caris Assure – a powerful, multi-functional blood-based assay that integrates whole exome and whole transcriptome sequencing with advanced machine learning to address the full spectrum of clinical testing from one wet-lab workflow.
Our findings highlight the platform’s robust capabilities:
Early Detection: Caris Assure demonstrated impressive sensitivities for stages I-IV cancers (83.1%, 86.0%, 84.4%, and 95.7% respectively), all achieved at a high specificity of 99.6%. Early stage sensitivity looks great!
Minimal Residual Disease (MRD) and Monitoring: The platform accurately predicts disease recurrence, with patients predicted to have an event showing significantly shorter disease-free survival (HR=33.4, p<0.005 for MRD; HR=4.39, p=0.008 for monitoring). Importantly, this is achieved through a tumor-naïve approach, removing the need for prior tumor tissue sequencing.
Therapy Selection: We observed high concordance (PPA of 93.8%, PPV of 96.8%) in detecting driver mutations for therapy selection from blood samples compared to matched tumor tissue, especially with CHIP subtraction.
AI-Powered Insights: The Assure Blood-based Cancer Detection AI (ABCDai) models leverage nine distinct feature sets, including novel liquid biopsy-specific features like Fragmentome, Motifome, Entropyome, PositionomeNU, and PositionomeTF, providing sensitive and specific signals.
This unified liquid biopsy platform represents a significant leap forward in multi-cancer early detection, disease monitoring, and precision therapy selection, holding immense potential to improve patient outcomes. Congrats to all the coauthors!
Title: Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors
Authors: J. Abraham, V. Domenyuk, N. Perdigones, S. Klimov, S. Antani, T. Yoshino, E. I. Heath, E. Lou, S. V. Liu, J. L. Marshall, W. S. El-Deiry, A. F. Shields, M. F. Dietrich, Y. Nakamura, T. Fujisawa, G. D. Demetri, A. Barker, J. Xiu, D. A. Sacchetti, S. Stahl, R. Hahn-Lowry, A. Stark, J. Swensen, G. Poste, D. D. Halbert, M. Oberley, M. Radovich, G. W. Sledge and David B. Spetzler
More posts featuring Matthew Oberley.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023